Merck Carotid Atherosclerosis Trial (MK-0000-111)(COMPLETED)

• Status: Completed
• Trial end date: 2010-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will examine the effect of statin and niacin therapy on carotid plaque biomarkers

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Atorvastatin; Atorvastatin Calcium; Niacin; Niacinamide; Nicotinic Acids; Simvastatin

Criteria

Inclusion Criteria:

• Patient is diagnosed with carotid stenosis AND is scheduled to undergo carotid endarterectomy

• Female patients of reproductive potential must abstain from sex or use an acceptable method of birth control through out the study

Exclusion Criteria:

• Patient must undergo CEA less than 4 weeks after entering study

• Patient has recent history of acute coronary syndrome

• Patient has has coronary artery bypass graft surgery within 30 days of study start

• Patient has thyroid disease that has not been treated for more than 6 weeks

• Patient has donated blood within 8 weeks of study start

• Patient has poorly controlled diabetes mellitis

• Patient has human immunodeficiency virus (HIV) or Hepatitis B or C

• Patient is taking warfarin or other anticoagulants

• Patient is taking hormone replacement therapy